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Lymphedema remains one of the most feared compli-
cations of breast cancer therapy, yet at the same time, is
arguably one of the least well understood. Review of the
literature reveals inconsistencies in defining and measuring
this condition, as well as in understanding the extent of
lymphedema that is clinically significant. The true inci-
dence of lymphedema is widely debated, as are the risk
factors leading to its development. The surgical removal of
lymph nodes and disruption of lymphatic channels during
dissection of the axilla clearly contribute, but there are
other variables that play a role, including treatment-related
variables such as use of radiation therapy, and patient-
related variables. Some of the most frequently reported
patient-related factors are increasing age, higher body mass
index, and weight gain. Although infection and injury have
been reported to be inciting events in the development of
lymphedema, these relationships are less clear.1,2
Attempting to address some of the shortcomings of the
existing literature, in the current issue of Annals of Surgical
Oncology, Yen et al. report their findings of risk factors for
development of lymphedema in a population-based study
of breast cancer patients over 65 years of age. Patients
were identified through Medicare claims which were
queried along with state tumor registries to extract clini-
copathologic data. The presence of lymphedema was a
self-reported measure and, at a median of 48 months
postoperatively, 193 (14.4%) women reported evidence of
lymphedema. After controlling for tumor size, histology,
type of surgery, and adjuvant therapies, the investigators
found that removal of more than five lymph nodes and
presence of lymph node metastases were independent
predictors of developing lymphedema. These data and the
authors’ conclusions raise several issues that warrant fur-
ther discussion as we seek to understand the relative
contributions of disease and therapeutic intervention in
breast cancer outcomes.
One thing that we can all agree on is that there is no
consensus on what quantitatively constitutes lymphedema.
Volume displacement or circumferential measurements of
the arm have been the most commonly employed methods
for assessing lymphedema; however, these methods have
not been standardized, and defining lymphedema based on
specific measurements may not be clinically relevant. Yen
and colleagues suggest that a potential weakness of their
study was the fact that lymphedema was a self-reported
outcome by the study participants. In fact, symptom
assessment may be an underutilized tool for identifying
patients with lymphedema. Patient’s may report that their
arm feels heavy before lymphedema is significant enough
to lead to stretching of the skin and subcutaneous tissue
that would be required to cause a change in volume or
circumferential measurement. Armer et al. have demon-
strated that there is a high predictive ability between
objective measures of extremity swelling and the self-
reported outcome of arm heaviness.3 A recent study by
Norman et al. also demonstrated that differences in self-
reported arm size and symptoms can be early signs of
progressing lymphedema.4 Subjective limb assessment,
including asking if their arm feels heavy, is an important
measure, and patients reporting arm heaviness should be
referred for appropriate evaluation by a physical therapist
with expertise in lymphedema management.
With respect to factors predisposing for the development
of lymphedema, Yen and colleagues determined that only
removal of more then five lymph nodes and presence of
lymph node metastases were significant. These findings
have important implications given current breast cancer
treatment recommendations. Sentinel lymph node dissec-
tion (SLND) is now routinely utilized for axillary staging
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in patients with early-stage breast cancer. Several multi-
center trials and large single-institution experiences have
reported that the median number of lymph nodes removed
during SLND ranges between 2 and 3.5–7 The data reported
by Yen et al. that removal of more than five lymph nodes is
what predisposes women to increased risk of lymphedema
might lead one to conclude that there is no increased risk
of lymphedema in patients undergoing SLND with fewer
than five lymph nodes recovered. We know from the
reports of the American College of Surgeons Oncology
Group (ACOSOG) sentinel lymph node trials and the
Axillary Lymphatic Mapping against Nodal Axillary
Clearance (ALMANAC) trial that this is not the case.
Lymphedema rates of approximately 7% and 5% at 1 year
after surgery have been reported for the ACOSOG Z0010
and ALMANAC trials, respectively.2,8 In studies reporting
on the development of lymphedema, there is significant
variability in the time between surgery and the develop-
ment of arm symptoms; therefore it is anticipated that the
rates in these trials may increase with longer follow-up. In
the population-based study by Yen et al., 319 patients
underwent SLND alone and 7% developed lymphedema.
This rate of lymphedema was similar to the rate of 5.7%
that was reported in the 20% of their cohort that did not
undergo any axillary surgery. These percentages must be
interpreted with caution, as the number of lymph nodes
removed, regardless of the axillary procedure, was highly
variable. For example, in the patients who reportedly had
no axillary surgery, the authors reported that the number of
lymph nodes evaluated ranged between 0 and 15. This
highlights the difficulty of using data extracted from large
databases where the investigators do not have the ability to
review the primary source documents for accuracy. Rec-
ognizing these limitations, the authors suggest that it is
important to counsel patients undergoing SLND regarding
their risk of developing lymphedema. While this is cer-
tainly an important part of preoperative education and
informed consent, it is important to remember that the
sentinel lymph node procedure is performed for staging
and that the accuracy of this staging procedure may be
impacted if the surgeon does not remove all of the sentinel
nodes. The number of sentinel nodes will vary from patient
to patient. Several investigators have attempted to deter-
mine the number of sentinel lymph nodes (SLN) that need
to be removed for accurate staging and have reported that
four or five nodes is enough. In a recent study from our
institution evaluating over 775 patients with a positive
SLN, we found that in 75% of patients the first SLN
removed was the one containing metastatic disease. In 91%
of patients, the first metastasis was identified in one of the
first two lymph nodes removed. Removal of five SLNs
allowed for recovery of[99% of all positive SLNs. These
data suggest that, in the majority of patients, removing up
to five SLNs will be adequate to appropriately stage the
axilla; however, additional clinical and pathologic factors
may impact this number and if additional blue or hot SLNs
remain after five are excised, then removal of more lymph
nodes may be required.7 With respect to the risk of
lymphedema following SLND, it may not be the number of
nodes that are removed but the extent of the dissection and
the number of lymphatic channels that are disrupted during
the recovery of the SLNs that predisposes a patient to the
risk of developing this condition.
The second risk factor reported by Yen et al. to predict
lymphedema was the presence of lymph node metastases.
In their discussion, the authors speculate that this may be
due to the addition of adjuvant therapies, including radia-
tion; however they argue against this for three reasons: (1)
they were unable to identify patients that underwent axil-
lary radiation, as radiation therapy billing codes do not
differentiate between treatment fields; (2) axillary radiation
is not routinely used in the adjuvant setting for women with
early-stage breast cancer; and (3) their statistical analysis
did not demonstrate an association between radiation
therapy and development of lymphedema. Again, the
reader should be cautioned since the authors note that their
ability to accurately determine the extent of radiation was
significantly limited. As per current guidelines, patients
with node-positive disease may receive adjuvant radiation
of the level III axilla and supraclavicular fossa as a com-
ponent of their treatment.9 It is also known that a
significant component of the level I and II axilla is within
the standard tangential breast irradiation fields utilized for
early-stage breast cancer patients treated with breast
radiation following lumpectomy.10 It is not a stretch to
assume that such treatment can cause radiation-induced
fibrosis leading to lymphatic obstruction and subsequent
lymphedema.
As clearly demonstrated in this study by Yen et al.,
lymphedema remains a potential morbidity of breast cancer
therapy regardless of our attempts to decrease the extent of
surgical intervention. To address the many inconsistencies
in our current understanding of the risk of developing
lymphedema, clinicians must reach a consensus on the
appropriate measures and timing of those measures. Well-
designed clinical trials incorporating those measures will
then be required to better determine the incidence, risk
factors, and appropriate treatment of lymphedema. Cur-
rently, one cooperative group trial (CALGB 70305: A
Randomized Study to Prevent Lymphedema in Women
Treated for Breast Cancer) is randomizing patients under-
going axillary lymph node dissection to one of two arms:
education only, or an education and treatment arm that will
include physical-therapy-focused interventions. We would
encourage surgeons caring for breast cancer patients to
consider enrolling their patients in this trial. Until the time
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that such studies are completed, surgeons should continue
to counsel their breast cancer patients about the risk of
lymphedema with surgical treatment and the need for early
intervention to minimize the extent of arm swelling that
may occur.
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